Market cap $278.68M
Enterprise value $24.03M
Revenue $0.00
EBITDA -$40.15
Income -$46.28
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E 6.18
Forward P/E N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales N/A
P/FCF N/A
Price/Book 116.09
Book/Share 0.00
Cash/Share 0.00
FCF yield -13.36%
Employees 21
RPE $0.00
Volume 8.194M / 50.829k
Relative vol. 161.21 ×
EPS N/A
EPS Q/Q -28.00%
Est. EPS Q/Q 6.25%
Ret. on assets -159.45%
Ret. on equity -584.98%
ROIC -98.65%
ROCE 684.23%
Volatility 40.77%
Beta 0.54
RSI 32.36
Range $0.07 – $0.07
52 weeks $0.01 – $0.75
SMA 50 $0 +80.00%
SMA 200 $0 +71.43%
1 year target $69 +97,757.14%
Mean Recomm. 1.80
Shares outst. 255.668M
Shares float 12.081M 4.73%
Short % of float 0.97%
Short ratio 1.07

Recent 9 Meters Biopharma news

Wednesday, 22 June 2022
 
bizjournals
Raleigh pharma sees stock tumble after stopping trial. Now what?
Thursday, 4 February 2021
 
zacks
9 Meters Biopharma is Overbought: Is A Drop Coming?
Wednesday, 2 December 2020
 
yahoo
Is 9 Meters Biopharma A Good Stock To Buy Now?
Monday, 13 July 2020
 
prnewswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
8-K 18 Jul 2023 Entry into a Material Definitive Agreement; Bankruptcy or Receivership; Triggering Events That Accelerate o...
8-K 16 Jun 2023 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K 30 May 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 22 May 2023 Other Events
8-K 19 May 2023 Entry into a Material Definitive Agreement; Triggering Events That Accelerate or Increase a Direct Financia...
8-K 15 May 2023 Results of Operations and Financial Condition; Financial Statements and Exhibits
10-Q 15 May 2023 Quarterly report
8-K 27 Apr 2023 Entry into a Material Definitive Agreement; Triggering Events That Accelerate or Increase a Direct Financia...
8-K 6 Apr 2023 Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Continued Listing R...
8-K 5 Apr 2023 Other Events; Financial Statements and Exhibits
10-K 28 Mar 2023 Yearly report
Insider
Trans.
Transaction
Price per share Total value
Bethany Sensenig Chief Financial Officer Sale 21 Apr 2023 $1.21 $11,011
John Temperato Chief Executive Officer Buy 6 Jul 2022 $0.23 $28,750
Mark A Sirgo Director Buy 1 Jul 2022 $0.25 $43,750
Michael T. Constantino Director Buy 23 May 2022 $0.48 $7,680
John Temperato Chief Executive Officer Buy 18 May 2022 $0.45 $22,500
Mark A Sirgo Director Buy 18 May 2022 $0.47 $50,000
Mark A Sirgo Director Buy 3 Mar 2022 $0.58 $50,140
John Temperato Chief Executive Officer Buy 3 Mar 2022 $0.56 $56,000
Mark A Sirgo Director Buy 2 Dec 2021 $0.89 $44,500
Mark A Sirgo Director Buy 18 Nov 2021 $1.06 $21,200
John Temperato Chief Executive Officer Buy 18 Nov 2021 $1.05 $52,500

1,348 people own 9 Meters Biopharma on Robinhood

Powered by Robintrack.

9 Meters Biopharma executives

Insider Age Since Compensation
John Temperato (56) Pres, CEO, and Director 56 $652,437
Dr. Patrick H. Griffin (66) Chief Medical Officer 66 $500,550
Edward J. Sitar CPA, CPA (58) Chief Financial Officer 58 $397,400
Sarah Liu M.B.A.
Albert J. Medwar M.B.A., MBA
Bethany Sensenig C.M.A., M.B.A.
Dr. Nir Barak M.D.
Dr. Elena Verdu M.D., Ph.D.
Dr. Ciaran P. Kelly M.D.
Joseph A. Murray
Dr. Peter H. R. Green M.D.
Dr. Nir Barak
Jerry Gardner
Sireesh Appajosyula Pharm.D. (45) Sr. VP of Corp. Devel. and Operations 45

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

  • Health Care > Biotechnology
  • 9 Meters Biopharma, Inc., 8480 Honeycutt Road, Raleigh 27615, United States
  • 919 275 1933
  • Investor relations

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Current assets
Cash $7.623578 $29.658932 $39.397542 $29.455788
Short term investments
Net receivables
Inventory
Total current assets $9.197303 $33.017849 $18.453599 $31.348098
Long term investments
Property, plant & equipment $0.106754 $0.122715 $0.139453 $0.1548
Goodwill & intangible assets
Total noncurrent assets $0.115734 $0.129995 $23.681609 $0.16038
Total investments
Total assets $9.313037 $33.147844 $42.135208 $31.508478
Current liabilities
Accounts payable $4.231034 $5.053073 $1.437685 $2.326017
Deferred revenue
Short long term debt $5.071143 $19.616313 $2.646
Total current liabilities $15.577469 $30.695905 $12.86282 $9.339816
Long term debt $0.034773 $0.051396 $15.811587 $0.08319
Total noncurrent liabilities $0.034773 $0.051396 $15.811587 $0.08319
Total debt $5.105916 $19.667709 $18.457587 $0.08319
Total liabilities $15.612242 $30.747301 $28.674407 $9.423006
Stockholders' equity
Retained earnings -$226.475539 -$212.607082 -$200.677179 -$191.322508
Other stockholder equity
Total stockholder equity -$6.299205 $2.400543 $13.460801 $22.085472
(in millions USD) 2022 2021 2020
Current assets
Cash $29.658932 $46.993285 $37.851388
Short term investments $0.075
Net receivables
Inventory
Total current assets $33.017849 $49.985233 $38.926975
Long term investments
Property, plant & equipment $0.122715 $0.182712 $0.225958
Goodwill & intangible assets
Total noncurrent assets $0.129995 $0.188292 $0.231538
Total investments $0.075
Total assets $33.147844 $50.173525 $39.158513
Current liabilities
Accounts payable $5.053073 $2.434452 $1.487948
Deferred revenue
Short long term debt $19.616313 $0.014216
Total current liabilities $30.695905 $8.45707 $6.848462
Long term debt $0.051396 $0.113142 $0.167938
Total noncurrent liabilities $0.051396 $0.113142 $0.167938
Total debt $19.667709 $0.113142 $0.182154
Total liabilities $30.747301 $8.570212 $7.0164
Stockholders' equity
Retained earnings -$212.607082 -$168.840667 -$132.061267
Other stockholder equity
Total stockholder equity $2.400543 $41.603313 $32.142113

Income statement

(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Revenue
Total revenue
Cost of revenue
Gross profit
Operating activities
Research & development $9.799291 $8.794695 $6.298501 $7.546477
Selling, general & administrative $2.9882 $1.946701 $2.417484 $3.648944
Total operating expenses $12.787491 $10.741396 $8.715985 $11.195421
Operating income -$12.787491 -$10.741396 -$8.715985 -$11.195421
Income from continuing operations
EBIT -$13.115637 -$10.110259 -$8.50733 -$11.130102
Income tax expense
Interest expense $0.75282 $1.819644 $0.847341
Net income
Net income -$13.868457 -$11.929903 -$9.354671 -$11.130102
Income (for common shares) -$13.868457 -$11.929903 -$9.354671 -$11.130102
(in millions USD) 2022 2021 2020
Revenue
Total revenue
Cost of revenue
Gross profit
Operating activities
Research & development $31.008151 $21.995291 $10.933023
Selling, general & administrative $11.0089 $9.662875 $10.519955
Total operating expenses $42.017051 $36.761919 $53.719871
Operating income -$42.017051 -$36.761919 -$53.719871
Income from continuing operations
EBIT -$41.099126 -$36.732212 -$57.450266
Income tax expense
Interest expense $2.667289 $0.047188 $4.046223
Net income
Net income -$43.766415 -$36.7794 -$61.496489
Income (for common shares) -$43.766415 -$36.7794 -$61.496489
(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Net income -$13.868457 -$11.929903 -$9.354671 -$11.130102
Operating activities
Depreciation $0.001329 $0.00254 $0.001569 $0.002787
Business acquisitions & disposals
Stock-based compensation $0.737 $0.744 $0.73 $1.774
Total cash flows from operations -$9.749676 -$9.73861 -$9.969952 -$7.786324
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $5
Net borrowings -$16.748001 $19.911706
Total cash flows from financing -$12.285678 $19.911706
Effect of exchange rate
Change in cash and equivalents -$22.035354 -$9.73861 $9.941754 -$7.786324
(in millions USD) 2022 2021 2020
Net income -$43.766415 -$36.7794 -$61.496489
Operating activities
Depreciation $0.008523 $0.007573 $0.018491
Business acquisitions & disposals -$2.493165 -$3.184454
Stock-based compensation $3.938 $2.413 $4.723
Total cash flows from operations -$37.243217 -$29.478275 -$19.409786
Investing activities
Capital expenditures -$0.002842 -$0.012476 -$0.002543
Investments $0.075
Total cash flows from investing -$0.002842 -$2.430641 -$3.186997
Financing activities
Dividends paid
Sale and purchase of stock $44.010135 $39.676329
Net borrowings $19.911706 -$0.058199 $0.015528
Total cash flows from financing $19.911706 $41.050813 $55.855239
Effect of exchange rate
Change in cash and equivalents -$17.334353 $9.141897 $33.258456

Recent institutional transactions

Quarter Shareholder Change
Shares owned
Shares
Value (in thousands USD)
2023 Q3 Strategic Investment Solutions, il
+6,200.00%
17,325 $2,284
2023 Q2 Sabby Management
Sold out
1,038,440 $697,832
2023 Q2 Vanguard Group Inc
Sold out
619,829 $416,526
2023 Q2 Laurion Capital Management L.P.
Opened
218,710 $146,973
2023 Q2 Two Sigma Securities
Sold out
13,844 $9,303
2023 Q2 Group One Trading, L.P.
Sold out
10,363 $6,964
2023 Q2 Fmr
Sold out
53 $36
2023 Q1 Northwestern Mutual Wealth Management Co
Sold out
2 $3
2022 Q4 Renaissance Technologies
Sold out
73,168 $92
2022 Q3 Laurion Capital Management L.P.
Sold out
4,558,200 $980

Institutional shareholders

Shareholder Stake
Shares owned
Shares
Value (in thousands USD)
Laurion Capital Management L.P. 1.87% 4,776,910
Sabby Management 0.41% 1,038,440
Millennium Management 0.38% 958,880
Vanguard Group Inc 0.24% 619,829
Renaissance Technologies 0.03% 73,168
Regentatlantic Capital 0.02% 41,322
Amalgamated 0.01% 36,861
Ashfield Capital Partners 0.01% 33,353
Frontier Wealth Management 0.01% 30,000
Citadel Advisors 0.01% 27,808